Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
They put a lot of effort in PT after the MHRA debacle. Now as PC1954 put nicely we 'have meat on the bones' then l dare say it should not be too difficult perhaps to raise circa 6 million to progress thus removing chronic SP decline caused by the RF finance.
As for the MAD part of trial 300 mg per day should pose very little or any safety concerns as preclinical could not establish an MTD at 30x treatment dose and the therapeutic treatment dosaging regime stated by Sareum of between 12.5 and 1000 mg per day.
Preclinical with 737 was put at around max of 1000 to 1200 mg per day, and whilst ok with few adverse effects the treatment when exceeding 1000mg to 1200mg per day adverse effects increased.
So Sareums preclinical dosing assessment proved to be pretty well spot on.
6 million to guarantee advancement of 1801 to end of phase 1b with the potential it has in psoriasis alone is peanuts and also now much reduced risk.
Regards to all.
Don't be surprised if there is similar buying next week PC1954.
We sit at 0.65p old money. Something has to give soon surely. A couple of hundred thousand shares sold and 5 million knocked off market cap.
In the past it has been on heavy drops there has been heavy buying. With exception of last couple of trades this has not been the case. More shares sold than can be sucked up by a company that has no concern for the borrower.
I will add more at these levels or lower with a Market Cap of around 22 million.
RF as we are aware have wiped over 50 million off the market cap Value on an already deflated price.
Regards to all.
1801 going well and news should follow soon of 737 developments.
Regards
Mms will be happy on trade volume.
Https://www.meipharma.com/pipeline.html
ME 344
Regards and those that have been here a while may remember the keen commitment NG had in pushing 737 to the point of stating that SRA737 may probe more commercially viable than Momoletonib. Not a happy person when 737 progress halted.
The whole affair still stinks to me.
Regards
Pretty certain that Nick Glover somewhere along the line associated with 737
https://www.linkedin.com/posts/nick-glover-5306351a_two-pronged-attack-on-dna-repair-could-kill-activity-6643904547318312961-vsJm
One if two drugs in their current pipeline address increasing effectiveness of Chk1 inhibitors
Https://www.linkedin.com/posts/nick-glover-5306351a_two-pronged-attack-on-dna-repair-could-kill-activity-6643904547318312961-vsJm
I am pretty certain thst Nick Glover has his finger in the pie with 737.
You are most welcome PC1954.
If we take May 2020 then around a month before that, that is the time that the for sale sign of 737 came down from the window so as to speak with the removal of 737 from SO website.
Nick Glover definitely had ambitions for 737 and if it is indeed MEI that is the party in question then funding will be needed. Raising of funds could be obtained by issuing new shares with a subsequent reflection of dilution on the share price.
Currently 500k shares value around 2 million dollars circa 1.5 million pounds with dilution look a tad high.
Now l would suggest whilst this is pure speculation my part, there is a potential agreement to be signed that will happen after the raising of funding. The subsequent value of the SP will follow. Possibly pushing the price down to around 2 to 2.5 dollars per share which then 500k shares would be allocated as part of the deal in the licence.
I will keep an eye on MEI closely for news updates.
It certainly adds up for me.
Regards.
9 Jan 2017 — Nick Glover, President and CEO of Sierra Oncology. "We are pleased to announce that the formal transfer of sponsorship to Sierra.
737 gave an unexpected surprise in anogenital cancers. You can glean this from a past RNS update should you care to look.
Time for a beer and a bite to eat.
Regards
Yes Nick Glover was CEO of Sierra Oncology at time of on licence!
https://www.prnewswire.com/news-releases/sierra-oncology-successfully-transfers-sponsorship-of-sra737-clinical-trials-610092045.html
Take a look at the link below gents.
https://investor.meipharma.com/news-releases/news-release-details/mei-pharma-present-design-ongoing-clinical-study-evaluating-me
MEI Pharmaceuticals look a prime candidate for 737.
Small company of circa 30 million market cap current SP around 4 dollars a share circa 7.5 million shares.
Delving into Metatastic colorectal cancers of colon, Rectum and Anus.
They have only 2 products in their pipeline and basically using in combo therapy to treat difficult to treat cancers.
It gets a little better. The key driver of SRA 737 whilst at Sierra Oncology before his resignation as CEO in 2020 was none other than Nick Glover. Surely it is not pure coincidence that Nick Glover resigned around the same time that SRA 737 development was halted by Sierra Oncology.
Nick Glover is a director of MEI Pharmaceuticals.
Nick Glover l believe was the CEO of Sierra Oncology/ Pronai Therapeutics when the onlicence of 737 took place in 2016.
Have a look at the link and see what you think.
Regards
My take on that Hbd is the CPF will have paid the patent servicing fees, unless of course it has been on licensed.
As you say a great deal of work was carried out by Sierra Oncology to which Michelle Garratt was an advisor.
The new licence info we have been given information on is basically a continuation of the old licence as similar milestone payments.
This does strike me as a little odd.
Maybe an ex director of SO involved? New company formed?
I will if can find time try and look at rcentlyl formed companies and approx market cap and number of shares issued. It does strike me as not too distant to the Acrivon deal for Prexasertib
100 million dollar fund raise was over subscribed so that had no problem with finance.
Prexasertib from memory was discontinued due to adverse effects mainly myocarditis of which no such events were attributed to SRA737 during the trials.
Also take into consideration that 737 was administered to clinical trial patients that had recieved previous therapies and realistically no other effective treatment available to them.
737 halted disease progression well. 737 effective at preventing new cancer growth until eventually resistance to CHK1 occurs whereby the Cancer then evades the p53 checkpoint and utilises a different pathway. Hence effectiveness very likely to have far greater efficacy when used in combo.
Much work was undertaken by Michelle Garrett and the University of Kent up to mid 2020.
Some news on licence development certainly would not go amiss.
Regards
Good posting as always from you PC1954.
Never a any reason to respond to you in a vitriolic way as a member suggested here that has contributed virtually nothing to this bb.
My line of thinking is that Sareum will have an option. Correct me if l am wrong but Sareum basically financed to end of 1a at the present.
Nothing can gain any value until a milestone us met.
Phase 1a opens the door via the compound being acceptable to proceed to the next level and hence removes a risk of failure.
Ideally we would run to end of phase 1b.
However, Sareum being in discussions with interested parties will have via informal discussions valuations at certain stages.
Hence successful phase 1b results great.
Previous post l have suggested that as from the end of phase 1a an onlicence may evolve.
Realistically the is the earliest point not just for a pharma to become involved due to data,provided but also as an alternative investment.
Until phase 1a data is realised then nothing of any substance can have a material effect on market cap and hence the SP.
I would like to think that Sareum are working on this and if they are then playing a very tight game.
I do not believe that sareum would release any info regarding due to the RF deal they are looking at alternative forms of finance. The market l believe would act very negatively to this.
Data is crucial and as they stated in 2022 AGM that is what the interested parties want.
The science side l have 100% confidence in their end product but their insight of ability to finance at or near an optimum time leaves vast room for improvement.
Regards
As much as said l will not be posting for a while until news on any front, l believe it us important to read and take note of the below link.
https://www.rbccm.com/en/gib/biopharma/episode/raising-capital-a-new-playbook-for-a-new-era-in-biotech
Regards
Shepardherdollar. I have been buying too!
I will co time to add and comfortably can add another 20k financially.
It is what it is caused by the k ock on effects of a senile corrupt old president in the US creating a war with Russia. The US have benefitted at the cost of severe financial problems in Europe.
Escalating energy prices. Caused by cutting off or to be more precise destruction of pipelines not destroyed by Russia. Inflation and difficulties arise.
As for Tim and Co raising funds at one time easy. That no longer the case.
How would Tim and Co be expected to predict this change in financial markets?
It is difficult for them. Remember when they took pay cuts to allow further development when funds were low.
Sareum have tried their damnest to overcome problems and we can take the MHRA debacle as one.
They are committed to achieving success with our compounds.
It galls me that some here who l used to regard as prominent Sareum investors seek blood from the board.
Yes the board could have raised money earlier on
And yes the investor could have sold at a high.
Who is at fault here.
I could have sold more at a high. But l can assure you one thing is that l have and will be buying at these levels.
I am sure the BoD are working on it. It will not be easy.
As l have said before the data from early stage trials are absolutely crucial.
Sareum will have an idea of what the compound is worth now with no data and also with positive data. Also of phase 1b data.
To get investors on board they need to know potential values of the compound on at least safety data and thus can be derived to a certain extent on informal discussions.
As we sit at the moment bugger all. Data required!
If you are positive then add if you not then sell.
No point in moaning!
I shall not be posting for a while. I have expressed the benefits which l believe very positive to what we have.
No point in posting anymore as immaterial until we get data results.
Regards to all faithful long term holders.
Value of company is based on initially the safety fata results of our compounds.
Preclinical was excellent with no MTD established and 30 times treatment dose was achieved with no difficulty.
How would you value the compound should we prove satisfactory safety data equal to or surpass Deucravacitinib?
Tyk2 Jak1 should prove far more effective in Tyk2 alone,
The addition of biomarker data will indicate areas that 1801 will prove to have most potential.
Put a value on 1801 with good data. How much will a player in this game pay?
Deucravacitinib an allosteric Tyk2 failed in UC so by definition is not as good as it was hyped up to be. All it did was to establish a satisfactory safety profile which of course is beneficial to us.
In Psoriasis l have 100% faith that our compound will outperform Deucravacitinib as has dual inhibition. It had been postulated years ago but again there were safety concerns of Jak1 2 and 3.
As we all know there is nothing as such as Jak1 only as all we have is selectivity over Jak2 and 3. That is all it can ever be. But selectivity can be improved. The compound is as strong as its weakest link. That denotes initially its safety profile.
Jak2 is deemed to have associated side effects.yet we have new compounds of Tyk2 znd Jak2 in development by a company which believe they can easily achieve better results than Deucravacitinib.
Tyk2 will interact with Jak2 so this may lessen the burden of Jak2 off target effects. I don't know. But then companies that go down this path have greater understanding than 5 years ago. Much greater understanding than me too!
I will put again. What value can you place on a compound that is equal to or not better performing Deucravacitinib?
Regards
There is no reason as to why 1801 can not go fron phase 1b to phase 3 study.
Phase l is toxicity/safety profile. Phase lb is small patient group phase very little different to phase 2 trial. Phase 2 looks at small numbers looking at efficacy in an indication, Phase 3 is larger patient numbers typically in the hundreds following satisfactory progress of phase 2 with no unsatisfactory results.
All importance safety data. If safety data is spot on with little to no toxicity at 300 mg per day and treatment profile delivers good efficacy at 100 mg per day in psoriasis then there would be no need for phase 2 in Psoriasis.
Just a scenario l am not saying this will happen just that l see it as a very real probability.
Regards
Good morning KoolKat15, no problem.
Yes indeed here is very frustrating.
Sareum have never experienced difficulty in obtaining decent from what l remember.
Delay caused by MHRA not help. War in Ukraine not help with corresponding rocket in price of energy.
Very heavy investment in military production. From memory around 2.5 trillion dollars spent on military equipment in 2022.
A vast proportion of this equipment is made by the US.
Military manufacturing companies have seen their SP triple on some cases.
Investors are attracted to thus as you will know as a steady gain with little to no risk is seen better than massive gain with moderate risk.
What we have has not changed with regards to a compound or compounds that have the potential to become commercially viable.
What has changed is peoples perception as an investor.
We are much further forward than 2021 when at a high. Nothing has changed with our compounds.
737 development has stopped and now looking like kick starting, of course if funding is readily available.
All AIM pharma suffered badly not by what they are researching and developing but by lack of suitable finance and investment.
It will return l believe as knock down severely overdone. As to when you most likely have a better idea than me and l don't think the 5 year period from 2021 is far out.
From.memory the options to the HNWI was around 2025/26.
The yanks are very content for a war to continue in Ukraine or indeed spread to Europe. They are more than happy to have NATO troops in Ukraine as long as they are not American. Effectively the US has created war with Russia using Ukranian people as cannon fodder.
Is it not better to concentrate on developments to save or improve people's lives as opposed to mass destruction?
Have a great weekend and l am very certain that on good data release we will indeed move upwards. At the very least on good data it will open up investment/finance opportunities far more tolerable than what we have now.
Regards
Nice to be informed l have got it wrong when in the past when we sat at sub 0.3 p in old money and was adding when l could and stating the price would be over a penny (pre dilution) over 2p over 3p or 4p and looking forward to the 10p party ( it never quite made it)
I believe the price dill rise significantly on good data results. I have added over 40 k shares in past few months that indicate my belief. Will continue to add without any undue stress.
I am not always right, that l will admit. Don't put me in the same light as that Workinginpharma either!
But koolkat surely even you should be able to string a sentence together that makes sense
'This share is not going nowhere fast'. If it is 'not going nowhere' then it must be going somewhere.
By all means if you are not happy here, and that is easy to deduce by the content of your posting then feel free to sell and move on.
I wish you all the best
Regards
Interesting if you look at the risk regarding phase levels to risk.
https://www.ourcrowd.com/learn/is-biotech-a-good-investment#:~:text=A%20Growing%20Industry&text=likely%20to%20increase.-,Research%20indicates%20that%20the%20industry%20is%20likely%20to%20grow%20at,13.96%25%20between%202023%20and%202030.&text=As%20with%20any%20rapidly%20growing,room%20for%20growth%20and%20investment.